BRIEF-Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial

Reuters
12 Feb
BRIEF-Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial

Feb 12 (Reuters) - Alto Neuroscience ANRO.N:

  • ALTO NEUROSCIENCE ANNOUNCES FAVORABLE OUTCOME FROM INTERIM ANALYSIS OF ALTO-300 PHASE 2B MAJOR DEPRESSIVE DISORDER TRIAL

  • ALTO NEUROSCIENCE INC -TOPLINE RESULTS ARE EXPECTED IN MID-2026

Source text: ID:nBw12H1ra

Further company coverage: ANRO.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10